Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.51 |
| ▸ | PPARA | Q07869 | 5/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6652833 | 0.95 | PPARG (0.53) | PPARGPPARAHTR7PARP1KCNA3 | |
| SCHEMBL6653822 | 0.95 | PPARG (0.53) | PPARGPPARAHTR7PARP1KCNA3 | |
| SCHEMBL6543200 | 0.93 | PPARG (0.50) | PPARGPPARAHTR7PARP1KCNA3 | |
| SCHEMBL6543177 | 0.93 | PPARG (0.50) | PPARGPPARAHTR7PARP1KCNA3 | |
| SCHEMBL4588196 | 0.90 | PPARG (0.56) | PPARGPPARAHTR7PARP1KCNA3 | |
| Hydrochloric Acid SCHEMBL7389013 | 0.89 | PPARG (0.56) | PPARGPPARAHTR7PARP1KCNA3 | |
| SCHEMBL4588233 | 0.87 | PPARG (0.53) | PPARGPPARAHTR7PARP1KCNA3 | |
| SCHEMBL4588645 | 0.86 | PPARG (0.51) | PPARGPPARAHTR7PARP1KCNA3 | |
| Hydrochloric Acid SCHEMBL4587862 | 0.86 | PPARG (0.53) | PPARGPPARAHTR7PARP1KCNA3 | |
| Hydrochloric Acid SCHEMBL7390226 | 0.85 | PPARG (0.52) | PPARGPPARAHTR7PARP1KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050148614-A1 | Combination of active ingredients for the treatment of senile dementia of the Alzheimer type | SANOFI-AVENTIS (FR) | 2005-07-07 | — | — | US | claimed |
| EP-0979079-B1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | claimed |
| US-20030092737-A1 | Combination of active ingredients for the treatment of senile dementia of the Alzheimer type | SANOFI-AVENTIS (FR) | 2003-05-15 | — | — | US | claimed |
| US-6344464-B1 | Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination | SANOFI-SYNTHELABO (FR) | 2002-02-05 | — | — | US | claimed |
| EP-1030671-A1 | COMBINATION OF ACTIVE PRINCIPLES, IN PARTICULAR OF TETRAHYDROPYRIDINS AND ACETYLCHOLINESTERASE INHIBITING AGENTS, FOR TREATING SENILE DEMENTIA SUCH AS ALZHEIMER DEMENTIA | SANOFI-SYNTHELABO (FR) | 2000-08-30 | — | — | EP | claimed |
| WO-1999025363-A1 | COMBINATION OF ACTIVE PRINCIPLES, IN PARTICULAR OF TETRAHYDROPYRIDINS AND ACETYLCHOLINESTERASE INHIBITING AGENTS, FOR TREATING SENILE DEMENTIA SUCH AS ALZHEIMER DEMENTIA | SANOFI-SYNTHELABO (FR) | 1999-05-27 | — | — | WO | claimed |
| US-7320982-B2 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-β 1 | SANOFI-AVENTIS (FR) | 2008-01-22 | — | — | US | disclosed |
| US-20050148614-A1 | Combination of active ingredients for the treatment of senile dementia of the Alzheimer type | SANOFI-AVENTIS (FR) | 2005-07-07 | — | — | US | disclosed |
| US-20040157868-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-beta 1 | SANOFI-AVENTIS (FR) | 2004-08-12 | — | — | US | disclosed |
| EP-0979079-B1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI SYNTHELABO (FR) | 2004-06-16 | — | — | EP | disclosed |
| US-6693118-B2 | E.G., 1-(2-(6,7-METHYLENEDIOXYNAPHTH-2-YL)-ETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6-TETRAHYDROPYRIDINE AND 1-2-(4-CYCLOHEXENYLPHENYL)-ETHYL)-4-(3-TRIFLUOROMETHYLPHENYL)-1,2,3,6 -TETRAHYDROPYRIDINE; apoptosis inhibition; treatment of graft rejection or of acute or chronic rheumatoid arthritis | SANOFI-SYNTHELABO (FR) | 2004-02-17 | — | — | US | disclosed |
| EP-1017385-B1 | USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-beta 1 | SANOFI SYNTHELABO (FR) | 2003-07-16 | — | — | EP | disclosed |
| US-20030092737-A1 | Combination of active ingredients for the treatment of senile dementia of the Alzheimer type | SANOFI-AVENTIS (FR) | 2003-05-15 | — | — | US | disclosed |
| EP-1017385-A1 | USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-beta 1 | SANOFI-SYNTHELABO (FR) | 2000-07-12 | — | — | EP | disclosed |
| EP-0979079-A1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI-SYNTHELABO (FR) | 2000-02-16 | — | — | EP | disclosed |
| US-5981754-A | TREATMENT OF ANOXIA, ALZHEIMER'S DISEASE, SENILE DEMENTIA, SUBCORTICAL DEMENTIA SUCH AS HUNTINGTON'S CHOREA AND PARKINSON'S DISEASE, DEMENTIA CAUSED BY AIDS, NEUROPATHY | SANOFI (FR) | 1999-11-09 | — | — | US | disclosed |
| WO-1998053821-A1 | USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-β1 | SANOFI-SYNTHELABO (FR) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998048802-A1 | USE OF TETRAHYDROPYRIDINE DERIVATIVES TO PREPARE MEDICINES FOR TREATING DISEASES CAUSING DEMYELINATION | SANOFI-SYNTHELABO (FR) | 1998-11-05 | — | — | WO | disclosed |
| EP-0837848-A1 | 4-ARYL-1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES HAVING NEUROTROPHIC AND NEUROPROTECTIVE ACTIVITY | SANOFI (FR) | 1998-04-29 | — | — | EP | disclosed |
| WO-1997001536-A1 | 4-ARYL-1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES HAVING NEUROTROPHIC AND NEUROPROTECTIVE ACTIVITY | SANOFI (FR) | 1997-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092737-A1 | Combination of active ingredients for the treatment of senile dementia of the Alzheimer type | ACHE, BCHE, PSEN1 | PPARG 1612/4885PPARA 1966/4885HTR7 106/4885 |
| US-20050148614-A1 | Combination of active ingredients for the treatment of senile dementia of the Alzheimer type | ACHE, PSEN1, PSEN2 | PPARG 1752/4885PPARA 1956/4885HTR7 71/4885 |
| US-20040157868-A1 | Use of 4-substituted tetrahydropyridines for the manufacture of medicaments acting upon TGF-beta 1 | TGFB1, TGFBR1, TGFB2 | PPARG 3146/4885PPARA 2134/4885HTR7 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.